Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370610 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30242559 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL26041870 | 0.80 | CNR2 (0.33) | — | |
| SCHEMBL19757602 | 0.80 | CYP4F2 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL19523845 | 0.76 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18493140 | 0.76 | CYP4F2 (0.46) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29447974 | 0.75 | ALDH1A1 (0.44) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL20953116 | 0.75 | KDM5B (0.37) | CYP4F2CYP4A11KDM5B | |
| SCHEMBL26199501 | 0.74 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30823741 | 0.74 | ALDH1A1 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221352-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | CYP4F2 3246/4885CYP4A11 2736/4885RXRA 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.